3hon MSN
Easy-to-use tool can identify high- and low-risk metastatic prostate cancer patients earlier
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...
News-Medical.Net on MSN
New trial aims to improve both survival and quality of life for men with advanced prostate cancer
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...
Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.
Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...
If a person has an "aggressive" prostate cancer with a Gleason score of 9, what does that mean? What's the outlook when it comes to survival rate and prognosis? Every cancer survivor is unique, of ...
Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...
BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and bone ...
Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...
Hypofractionation of radiation therapy in men with high-risk prostate cancer is not associated with worse overall survival or prostate cancer mortality. Survival outcomes are comparable after ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback